Should NOACs Be Monitored Like Warfarin . . . by Pharmacists? Should NOACs Be Monitored Like Warfarin . . . by Pharmacists?

Dr John Mandrola describes the results of a trial studying adherence to dabigatran, which he calls "disruptive." theheart.org on Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology Expert Column Source Type: news